NCT05644379

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma

An Open, Single-arm, Single-centre Clinical Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Intermediate to Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of Cadonilimab Injection in combination with Regorafenib in the treatment of intermediate to advanced hepatocellular carcinoma that has failed at least one prior systemic therapy .

Detailed description

An open, single-arm, single-centre clinical study evaluating Cadonilimab Injection in combination with Regorafenib for the treatment of intermediate to advanced hepatocellular carcinoma that has failed at least one prior systemic therapy.

Conditions

• Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy

Interventions

Type	Name	Description
DRUG	Cadonilimab Injection	Cadonilimab Injection, 6mg/kg, intravenous drip ,q2w,
DRUG	Regorafenib	Regorafenib 80mg, po, orally once daily

Timeline

• Start date: 2022-11-24
• Primary completion: 2025-11-01
• Completion: 2026-11-01
• First posted: 2022-12-09
• Last updated: 2026-02-09

Locations

1 site across 1 country: China